3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Lung Neoplasms
5
Neoplasms
4
Thoracic Neoplasms
3
Respiratory Tract Neoplasms
3
Lung Diseases
3
Bronchial Neoplasms
3
Breast Neoplasms
3
Breast Diseases
3
Neoplasms, Glandular and Epithelial
2
Neoplasms by Histologic Type
2
Melanoma
2
Kidney Neoplasms
2
Endocrine Gland Neoplasms
2
Digestive System Neoplasms
2
Wilms Tumor
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thymoma
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Sarcoma, Kaposi
1
Sarcoma
1
Interventions
Pemetrexed
7
Carboplatin
7
Cisplatin
5
pembrolizumab
4
durvalumab
4
osimertinib
3
Paclitaxel
3
selpercatinib
2
pralsetinib
2
cobimetinib
2
Radiosurgery
2
Erlotinib Hydrochloride
2
130-nm albumin-bound paclitaxel
2
trametinib
1
taletrectinib
1
sotorasib
1
repotrectinib
1
patritumab
1
napabucasin
1
glutathione pegylated liposomal doxorubicin
1
ficlatuzumab
1
exemestane
1
enzalutamide
1
entinostat
1
dabrafenib
1
ceralasertib
1
cemiplimab
1
camrelizumab
1
atezolizumab
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
entinostat
×
Thoracic
×
Clear all
NCT01594398
2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1
Completed
14 enrolled